Cell-Based, Chronic Wound Gene Therapy for Older Adults
Cell-Based, Chronic Wound Gene Therapy for Older Adults
批准号:
6932633
负责人:
Christina Lea Thomas-Virnig
金额:
$17.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-06-15 至 2006-05-31
关键词:
biotechnologycell linecell migrationcell proliferationclone cellscollagenasecytogeneticsenzyme activityenzyme induction /repressiongene expressiongene therapyhuman old age (65+)human tissuekeratinocytemetalloendopeptidasesproteolysisskin ulcertherapy design /developmenttissue engineeringtissue inhibitor of metalloproteinasestransfection /expression vectorwound healing
中文摘要
描述(由申请人提供):根据伤口愈合协会,在美国约15%的老年人患有慢性,难以愈合的皮肤伤口。蛋白水解活性的增加与内在的皮肤老化有关,使老年人易于组织分解。此外,慢性伤口固有地表现出高度蛋白水解的环境,导致细胞外基质、关键的可溶性或基质相关生长因子及其各自的细胞受体的异常降解。因此,老化皮肤的蛋白水解性质不仅导致急性伤口愈合受损,而且使老年人现有的慢性皮肤伤口永久化。减弱慢性伤口的高度蛋白水解环境的策略具有显著增强这些难以愈合的伤口的愈合的潜力。
迄今为止,尚未开发和销售专门针对慢性伤口的蛋白水解性质的生物治疗选择。在该I期可行性确定中,我们建议生成并表征经遗传修饰以组成型表达功能性生物活性蛋白酶抑制剂的人角质形成细胞系。该细胞试剂旨在最终用于ESTGRAFT(TM)shieid,这是一种基于细胞的基因治疗产品,旨在对抗与老年人慢性皮肤伤口相关的过度蛋白水解活性。Stratatech公司在获得专利的人类角质形成细胞系的离体基因工程方面取得的进展使其处于独特的位置来完成这项工作。在成功完成I期目标后,我们将扩大我们的研究,在随后的II期临床前试验期间在体外和体内检查候选细胞试剂产生的组织。
英文摘要
DESCRIPTION (provided by applicant): According to the Wound Healing Society, about 15% of older adults in the United States suffer from chronic, hard-to-heal skin wounds. An increase in proteolytic activity is associated with intrinsic cutaneous aging predisposing the elderly to tissue breakdown. Furthermore, chronic wounds inherently exhibit a highly proteolytic environment resulting in abnormal degradation of the extracellular matrix, critical soluble or matrix-associated growth factors, and their respective cellular receptors. Therefore, the proteolytic nature of aged skin not only contributes to impaired acute wound healing, but perpetuates existing chronic cutaneous wounds in older adults. Strategies to attenuate the highly proteolytic environment of chronic wounds have the potential to dramatically enhance the healing of these hard-to-heal wounds.
To date no biological treatment options specifically targeting the proteolytic nature of chronic wounds have been developed and marketed. In this Phase I feasibility determination, we propose to generate and characterize a human keratinocyte cell line genetically-modified to constitutively express a functional, bioactive proteinase inhibitor. This cellular reagent is intended for eventual use in ExpressGraft(tm)shieid, a cell-based gene therapy product engineered to combat the excess proteolytic activity associated with chronic cutaneous wounds in the elderly. Advances in ex vivo genetic engineering of a patented human keratinocyte cell line at Stratatech Corporation has made it uniquely positioned to complete this work. Upon successful completion of Phase I objectives, we will expand our studies to examine tissue generated from candidate cellular reagents both in vitro and in vivo during subsequent Phase II preclinical testing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金